|
Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery Clinical research trials and Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery. Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery clinical trial. Human subjects frequently get the finest healthcare available for their Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery  Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery
Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery
For Condition: Recurrent Melanoma,Stage 4 Melanoma
Status: Completed
Sponsor(s): Saint Francis Memorial Hospital ,
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as interleukin-2 and interferon alfa stimulate a person's white blood cells to kill cancer cells or may interfere with the growth of cancer cells. Combining chemotherapy with biological therapies may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of temozolomide followed by sargramostim, interleukin-2, and interferon alfa in treating patients who have stage IV melanoma that cannot be treated with surgery.
Details: OBJECTIVES: - Determine the response rate, time to progression, and survival of patients with unresectable stage IV melanoma treated with temozolomide followed by sargramostim (GM-CSF), interleukin-2, and interferon alfa. - Determine the safety and tolerability of this regimen in this patient population. - Determine the changes in quality of life over time in patients treated with this regimen. OUTLINE: This is a multicenter study. Patients receive oral temozolomide on days 1-5, and sargramostim (GM-CSF), interleukin-2, and interferon alfa subcutaneously on days 6-17. Treatment repeats every 28 days for 4-8 courses in the absence of disease progression or unacceptable toxicity. Patients with at least stable or responsive disease after 8 courses of therapy may receive additional therapy at investigators discretion. Quality of life is assessed at baseline, every 8 weeks during study, and then at 1 month after study. Patients are followed at 1 month, every 3 months for 2 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 14-30 patients will be accrued for this study within 2 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed unresectable stage IV melanoma - Measurable metastatic disease - No uncontrolled brain metastases PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - Karnofsky 70-100% Life expectancy: - More than 12 weeks Hematopoietic: - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 - Hemoglobin at least 10 g/dL Hepatic: - Bilirubin no greater than 1.5 times upper limit of normal (ULN) - SGOT and SGPT no greater than 3 times ULN - Alkaline phosphatase no greater than 3 times ULN Renal: - BUN no greater than 1.5 times ULN - Creatinine no greater than 1.5 times ULN Cardiovascular: - No significant cardiovascular disease Other: - No non-malignant systemic disease - No acute infection requiring IV antibiotics - No alcohol or substance abuse - No other condition, disease, or history of other illness that would preclude study participation - No hypersensitivity, allergic reactions, or intolerance to study drugs - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - At least 4 weeks since prior immunotherapy - No prior interleukin-2 - No other concurrent immunotherapy - No concurrent investigational vaccines or immunomodulatory agents - No other concurrent growth factors Chemotherapy: - At least 4 weeks since prior chemotherapy - No prior temozolomide - No other concurrent anticancer chemotherapy Endocrine therapy: - No concurrent steroids (including corticosteroids) Radiotherapy: - At least 4 weeks since prior radiotherapy Surgery: - See Disease Characteristics - At least 3 weeks since prior major surgery Other: - At least 30 days since prior immune-based therapy - No concurrent participation in other clinical trials with investigational drugs - No other concurrent anticancer drugs - No concurrent immunosuppressive therapy - No concurrent levamisole or cimetidine
Total Enrollment:
Location and Contact Information:
Overall Study Official:
LynnSpitler, Study Chair, Saint Francis Memorial Hospital
Saint Francis Memorial Hospital
San Francisco, California, 94109
United States
University of Colorado Cancer Center at University of Colorado Health Sciences Center
Aurora, Colorado, 80010
United States
John Wayne Cancer Institute at Saint John's Health Center
Santa Monica, California, 90404
United States
Additional Information:
Study ID Numbers: CDR0000067958; NCI-V00-1591,SFMH-BB-IND-5301
Study Start Date:
Record last reviewed: December 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00014092
Other Stage 4 Melanoma Studies:
1. Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the Brain
2. Boron Neutron Capture Therapy in Treating Patients With Melanoma
3. Vaccine Therapy in Treating Patients With Metastatic Melanoma
4. Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer
5. Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma
Related Studies:
Other Stage 4 Melanoma Clinical Trials
Other California Clinical Trials
Other San Francisco Clinical Trials
Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery
|
|
|
|
|
|
|
|
